DONG-A ST CO.,LTD
Financials
Valuation Metrics
DONG-A ST CO.,LTD's Market Cap is ₩3624B. At end of 2025 it was ₩4871B. Ranked #556 of 2,436 in KR market (top 23%), #337 of 787 on KOSPI (top 43%), #62 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 362.36B KRW | KR#556/2,436 Sec#62/234 |
| Revenue | 830.27B KRW | KR#444/2,436 Sec#18/234 |
| Net Income | -17.41B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 1.36T KRW | KR#390/2,436 Sec#18/234 |
| Net Assets | 681.82B KRW | KR#383/2,436 Sec#26/234 |
| Employees | 1,695 | KR#163/2,436 Sec#9/234 |
| Value | ||
| P/B | 0.53x | KR#865/2,436 Sec#38/234 |
| P/S | 0.44x | KR#828/2,436 Sec#27/234 |
| EV/EBITDA | 46.89x | KR#1,330/2,436 Sec#89/234 |
| FCF Yield | 1.56% | KR#1,102/2,436 Sec#76/234 |
| Profitability | ||
| ROE | -2.55% | KR#1,647/2,436 Sec#117/234 |
| ROA | -1.28% | KR#1,629/2,436 Sec#114/234 |
| Op. Margin | 1.59% | KR#1,412/2,436 Sec#103/234 |
| Revenue Growth | 11.80% | KR#858/2,436 Sec#74/234 |
| Earnings Growth | -333.04% | KR#1,580/2,436 Sec#103/234 |
| Financial Health | ||
| Debt Ratio | 98.78% | KR#321/2,436 Sec#39/234 |
| Total Debt | 484.57B KRW | KR#303/2,436 Sec#10/234 |
| FCF | 5.64B KRW | KR#872/2,436 Sec#58/234 |
| Cash | 228.61B KRW | KR#246/2,436 Sec#9/234 |
| Current Ratio | 1.50x | KR#1,313/2,436 Sec#142/234 |
| Net Debt/EBITDA | 19.41x | KR#1,422/2,436 Sec#101/234 |
| Dividend | ||
| Div. Yield | 1.87% | KR#939/2,436 Sec#49/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -15.09% | KR#1,107/2,436 Sec#84/234 |
| 1M Return | 5.67% | KR#439/2,436 Sec#37/234 |
| From 52W High | -34.02% | KR#533/2,436 Sec#36/234 |
| 1Y MDD | -41.95% | KR#593/2,436 Sec#45/234 |
| Trading | ||
| Volume | 15,425 shares | KR#1,970/2,436 Sec#196/234 |
| Foreign Own. | 19.86% | KR#227/2,436 Sec#11/234 |
| Per Share | ||
| EPS | -1,199 KRW | KR—/2,436 Sec—/234 |
| BPS | 67,799 KRW | KR#190/2,436 Sec#11/234 |
Company Info
Dong-A ST was established in 2013 as a spin-off from Dong-A Socio Holdings and acquired a global ADC specialist in 2023 to secure technology and pipelines. The company manufactures and sells developed new drugs such as STILLEN, Zydena, and Motilitone, along with specialized pharmaceuticals like Growtropin and Gaster, produced at its Cheonan, Daegu, and Songdo campuses. Dong-A ST is expanding R&D investment to develop new drugs for metabolic diseases including diabetes, obesity, and MASH, thereby strengthening its market dominance with a diverse portfolio. Dong-A ST is headquartered in Dongdaemun-gu, Seoul.